



201 Technology Drive • Irvine • California • 92618  
Telephone: (949) 450-5400  
Facsimile: (949) 450-5300  
Email: [IR@endocare.com](mailto:IR@endocare.com)  
Website: [www.endocare.com](http://www.endocare.com)

FOR RELEASE February 26, 2008 at 6:00 am EST

Investor Contact:

Matt Clawson  
Allen & Caron, Inc.  
(949) 474-4300  
[matt@allencaron.com](mailto:matt@allencaron.com)

Media Contact:

Len Hall  
Allen & Caron, Inc.  
(949) 474-4300  
[len@allencaron.com](mailto:len@allencaron.com)

For Additional Information:

Craig T. Davenport, CEO  
Michael R. Rodriguez, CFO  
Endocare, Inc.  
(949) 450-5400

**ENDOCARE SETS DATE FOR 2007 FOURTH QUARTER AND YEAR-END  
RESULTS RELEASE AND CONFERENCE CALL**

IRVINE, CA (February 26, 2008) . . . Endocare, Inc. (NASDAQ: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, plans to issue a press release announcing its financial results for the fourth quarter and year ended December 31, 2007, before the market opens on Tuesday, March 4, 2008, and to host a conference call to be webcast live on the Company's website ([www.endocare.com/investors/webcasts.php](http://www.endocare.com/investors/webcasts.php)) at 11:00 a.m. Eastern Time that same day.

Web participants are encouraged to go to the Company's website ([www.endocare.com/investors/webcasts.php](http://www.endocare.com/investors/webcasts.php)) at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The online archived replay will be available immediately following the conference call at [www.endocare.com/investors/webcasts.php](http://www.endocare.com/investors/webcasts.php).

**About Endocare**

Endocare, Inc.—[www.endocare.com](http://www.endocare.com)— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###